Abstract��OBJECTIVE To investigate the effect of transgelin 2 on paclitaxel resistance, migration and invasion in MCF-7/PTX cells. METHODS The morphology of MCF-7/S and MCF-7/PTX cells was observed under light microscope. Cell viability was determined using MTT method. The protein and mRNA expressions of transgelin 2, EMT markers including E-cadherin, N-cadherin and Vimentin in breast cancer cells were detected by Western blot assay and real-time PCR assay. Wound healing scratch assay and transwell invasion assay were performed to analyze migratory and invasive capability of cells, respectively. Transgelin 2 was reduced in MCF-7/PTX cells by transfecting with TAGLN2 small interference RNA(siRNA). RESULTS EMT process existed in MCF-7/PTX cells and these cells achieved a high degree of resistance to paclitaxel, and possessed strong ability of migration and invasion. TAGLN2 siRNA treatment sensitized the MCF-7/PTX cells to paclitaxel, and inhibited migration and invasion. CONCLUSION Overexpression of transgelin 2 could not only induce the paclitaxel resistance, but also inhibit migration and invasion in MCF-7/PTX cells, suggesting that transgelin 2 may serve as a novel biomarker and therapeutic target for breast cancer.
COUGHLIN S S, EKWUEME D U. Breast cancer as a global health concern [J]. Cancer Epidemiol, 2009, 33(5): 315-318.
[2]
SHI X P, MIAO S, WU Y, et al. Resveratrol sensitizes tamoxifen in antiestrogen-resistant breast cancer cells with epithelial-mesenchymal transition features [J]. Int J Mol Sci, 2013, 14(8): 15655-15668.
[3]
QU C, ZHANG W, ZHENG G, et al. Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells [J]. Mol Cell Biochem, 2014, 386(1): 63-71.
[4]
YOULDEN D R, CRAMB S M, DUNN N A, et al. The descriptive epidemiology of female breast cancer: An international comparison of screening, incidence, survival and mortality [J]. Cancer Epidemiol, 2012, 36(3): 237-248.
[5]
REN J, CHEN Y, SONG H, et al. Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line [J]. J Cell Biochem, 2013, 114(6): 1395-1403.
[6]
YANG Q, HUANG J, WU Q, et al. Acquisition of epithelial-mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells [J]. Br J Cancer, 2014, 110(8): 1958-1967.
[7]
MA J, FANG B, ZENG F, et al. Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells [J]. Oncotarget, 2015, 6(3): 1740-1749.
[8]
LI H, WANG Z, ZHANG W, et al. VGLL4 inhibits EMT in part through suppressing Wnt/beta-catenin signaling pathway in gastric cancer [J]. Med Oncol, 2015, 32(3): 83.
[9]
LI J, WANG Y, SONG Y, et al. miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells [J]. Mol Cancer, 2014, 13(1): 193.
[10]
SAKAMOTO J, MATSUI T, KODERA Y. Paclitaxel chemotherapy for the treatment of gastric cancer [J]. Gastric Cancer, 2009, 12(2): 69-78.
[11]
CHEN S, DONG Q, HU S, et al. Proteomic analysis of the proteins that are associated with the resistance to paclitaxel in human breast cancer cells [J]. Mol Biosyst, 2014, 10(2): 294-303.
[12]
CHEN S Y, CAI J X, ZHANG W P, et al. Proteomic analysis of proteins associated with the paclitaxel-induced drug-resistant human breast cancer cells[J]. Chin Pharm J(�й�ҩѧ��־), 2014, 49(10): 825-832.
[13]
CAI J, CHEN S, ZHANG W, et al. Paeonol reverses paclitaxel resistance in human breast cancer cells by regulating the expression of transgelin 2 [J]. Phytomedicine, 2014, 21(7): 984-991.
[14]
KAWAKAMI K, ENOKIDA H, CHIYOMARU T, et al. The functional significance of miR-1 and miR-133a in renal cell carcinoma [J]. Eur J Cancer, 2012, 48(6): 827-836.
[15]
ZHOU L, ZHANG R, ZHANG L, et al. Upregulation of transgelin is an independent factor predictive of poor prognosis in patients with advanced pancreatic cancer [J]. Cancer Sci, 2013, 104(4): 423-430.
[16]
CHEN S Y, HU S S, DONG Q, et al. Establishment of paclitaxel-resistant breast cancer cell line and nude mice models, and underlying multidrug resistance mechanisms in vitro and in vivo[J]. Asian Pac J Cancer Prev, 2013, 14(10): 6135-6140.
[17]
SONG H M, LEE J E,KIM J H. Ubiquitin C-terminal hydrolase-L3 regulates EMT process and cancer metastasis in prostate cell lines [J]. Biochem Biophys Res Commun, 2014, 452(3): 722-727.
[18]
YANG Q, WANG Y, LU X, et al. MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells [J]. Oncotarget, 2014, 6(5):3268-3279.
[19]
YU J W, LU Z H, GAO J, et al. Research progress in chemoresistance mechanism of paclitaxel and the future direction[J]. Chin Pharm J (�й�ҩѧ��־), 2013, 48(14):1147-1150.
[20]
WANG H, XU C, KONG X, et al. Trail resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer [J]. PLoS One, 2014, 9(6): e99067.
[21]
PRINJHA R K, SHAPLAND C E, HSUAN J J, et al. Cloning and sequencing of cDNAs encoding the actin cross-linking protein transgelin defines a new family of actin-associated proteins[J]. Cell Motil Cytoskeleton, 1994, 28(3): 243-255.
[22]
YOSHINO H, CHIYOMARU T, ENOKIDA H, et al. The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer [J]. Br J Cancer, 2011, 104(5): 808-818.
[23]
ZHANG Y, YE Y, SHEN D, et al. Identification of transgelin-2 as a biomarker of colorectal cancer by laser capture microdissection and quantitative proteome analysis[J]. Cancer Sci, 2010, 101(2):523-529.
2016, Vol. 51 
